Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$119.15 USD
+0.15 (0.13%)
Updated Sep 6, 2024 03:59 PM ET
After-Market: $119.16 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
Ascendis Pharma A/S [ASND]
Reports for Purchase
Showing records 81 - 100 ( 303 total )
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q4/FY22: SKYTROFA Growth Continues; All Eyes on TC-PTH/HP PDUFA in April
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Vision 3x3 Comes Into Focus; Ophthalmology Selected as New Therapeutic Area
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
FDA Allows Expanded Access Program for TC-PTH Ahead of April 30, 2023 PDUFA
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Key Takeaways from Ph2 ACcompliSH Data Follow-Up Call for TC-CNP/ACH
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Positive TC-CNP & Early TC-TLR7/8 Agonist Data Highlight TransCon''s Versatility
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q3: SKYTROFA Sales Take Off; Multiple Value-Driving Catalysts in Q4
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A